Related Experiment Video
Updated: Sep 27, 2025

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
Recurrent Alterations in the MAPK pathway in Sporadic Pyogenic Granuloma of Childhood
Katharina Strobel, Katja Maurus, Henning Hamm
1Department of Dermatology, University Hospital Würzburg, Josef-Schneider-Str. 2, DE-97080 Würzburg, Germany. wobser_m@ukw.de.
Abstract:
Pyogenic granuloma is one of the most common vascular tumours. The cause of pyogenic granuloma was previously thought to be an inflammatory reaction with consecutive stimulation of endothelial cell proliferation. However, recent studies suggest that pyogenic granuloma may be driven by constitutive activation of the mitogen-activated protein kinase pathway. The aim of this study was to investigate the molecular profile of sporadic pyogenic granuloma of childhood, using a systematic approach scrutinizing potential aberrations within different oncogenic pathways. Within a retrospective setting pyogenic granuloma of 15 patients was analysed by targeted next generation sequencing using the Oncomine Focus Assay, which includes genes of key tumorigenic signalling pathways. Activating mutations were found in 4 out of 15 cases (27%). Two HRAS hotspot mutations (p.Gly13Arg, p.Ala59Thr), 1 BRAF (p.Val600Glu) mutation and a novel, previously not reported, MAP2K1 hotspot mutation (p.Glu203Lys) were identified. It is notable that all of these genes are involved in constitutive mitogen- activated protein kinase signalling. This study increases the range of underlying genetic alterations in pyogenic granuloma by identifying novel oncogenic mutations in crucial mitogen-activated protein kinase pathway genes. The results provide supporting evidence that activated mitogen-activated protein kinase signalling is a key driver in the pathogenesis of pyogenic granuloma, which might be exploited by targeted treatment approaches for selected cases.
Insights
Pyogenic granulomas in children may be driven by specific gene mutations. Identifying these genetic alterations in the mitogen-activated protein kinase pathway could lead to targeted treatments.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Pyogenic granuloma is a common vascular tumor.
- Previously thought to be inflammatory, recent research suggests a role for mitogen-activated protein kinase (MAPK) pathway activation.
Purpose of the Study:
- To investigate the molecular profile of childhood pyogenic granuloma.
- To identify potential genetic aberrations in oncogenic pathways.
Main Methods:
- Retrospective analysis of 15 pediatric pyogenic granuloma cases.
- Targeted next-generation sequencing using the Oncomine Focus Assay.
Main Results:
- Activating mutations were identified in 27% (4/15) of cases.
- Mutations included HRAS, BRAF, and a novel MAP2K1 hotspot mutation.
- All identified mutations are involved in MAPK signaling.
Conclusions:
- Constitutive MAPK signaling is a key driver in pyogenic granuloma pathogenesis.
- Novel oncogenic mutations in MAPK pathway genes have been identified.
- These findings may inform targeted treatment strategies for pyogenic granuloma.
More Related Videos
10:13Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
Published on: August 12, 2014
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Related Concept Videos
MAPK Signaling Cascades
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Abnormal Proliferation
cAMP-dependent Protein Kinase Pathways
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Mitogens and the Cell Cycle